VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter to discuss the findings. According to Volition, multiple studies have demonstrated that its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality.
Most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. The company believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. Sepsis remains a leading cause of death worldwide, and early detection is critical for improving patient outcomes.
Volition's Nu.Q NETs assay measures nucleosomes released during NETosis, a process where neutrophils form web-like structures to trap pathogens. Elevated levels of H3.1 nucleosomes have been linked to disease severity in sepsis, making the test a potential tool for clinicians to assess patient risk and guide treatment decisions. The test's simplicity and cost-effectiveness could enable broader adoption in clinical settings, particularly in resource-limited environments.
For more details, the full press release is available at https://ibn.fm/2IH3m. Volition is a multinational company focused on advancing epigenetics, developing blood tests for early detection and monitoring of diseases such as cancers and sepsis. The company's research and development activities are centered in Belgium, with offices in the U.S. and London. Media inquiries can be directed to Louise Batchelor at mediarelations@volition.com. Further information is available on the company's website at https://volition.com/.
